Showing 9211-9220 of 9545 results for "".
- Star Scientific's Rock Creek Pharmaceuticals, Inc. Launches New Producthttps://practicaldermatology.com/news/20120926-star_scientifics_rock_creek_pharmaceuticals_inc_launches_new_product/2459728/Star Scientific, Inc., through its wholly owned subsidiary Rock Creek Pharmaceuticals, Inc., announced the new Anatabloc face cream, which is available on the cosmetic portion of the Anatabloc website and in select dermatology practices. The pro
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree
- Suneva Medical Launches ReGenica Skincarehttps://practicaldermatology.com/news/20120809-suneva_medical_launches_regenica_skincare/2459753/Suneva Medical launched ReGenica Skincare, a three-product rejuvenation system, that contains a variety of proteins and growth factors in a serum-free solution known as Multipotent CCM Complex, says the company. In one study, ReGenica Advanced Re
- Cone Health Pioneers Use of Fabric That Healshttps://practicaldermatology.com/news/20120726-cone_health_pioneers_use_of_fabric_that_heals/2459762/Studies find that hospital linens and gowns can be transformed into therapeutic tools when made with a smooth, antimicrobial fabric called DermaTherapy. Researchers found that patients using DermaTherapy developed 81.5 percent fewer be
- Makucell Unveils Renewnthttps://practicaldermatology.com/news/20120627-makucell_unveils_renewnt/2459779/Makucell, Inc., a pioneering regenerative biotechnology company, recently released the Renewnt (pronounced “Re-new-int”) brand. Renewnt's proprietary ingredient, Asymmtate, is a new approach to cellular aging, optimizing signals in the Wnt (pronounced “
- GlaxoSmithKline Launches Combination Trials for Metastatic Melanomahttps://practicaldermatology.com/news/20120604-glaxosmithkline_launches_combinations_trial_for_metastatic_melanoma/2459792/GlaxoSmithKline has begun a Phase III program evaluating the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with BRAF mutation-positive metastatic cutaneous melanoma. The COMBI-d (Combination of MEK and B
- Merz Realignment Focuses on Synergieshttps://practicaldermatology.com/news/20120518-merz_realignment_focuses_on_synergies/2459796/Merz is realigning and integrating its core businesses in the United States and Canada into one organization, with a single leadership team, the company announced. According to Merz, "the newly aligned structure is designed to stre
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom
- Mylan, Impax Win Ruling in Doryx Generics Patent Casehttps://practicaldermatology.com/news/20120502-mylan_impax_win_ruling_in_doryx_generics_patent_case/2459810/Mylan Inc. (MYL) said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn't infringe a patent held by Warner Chilcott (WCRX) Plc.
- PhotoMedex Completes Sale of Common Stock for $40 Millionhttps://practicaldermatology.com/news/20120430-photomedex_completes_sale_of_common_stock_for_40_million/2459812/PhotoMedex, Inc. (NasdaqGS: PHMD) expects gross proceeds of $40 million, before deducting underwriting discounts, commissions and other offering expenses, from recent sale of shares of common stock. The company closed concurrent registered offerin